Format

Send to

Choose Destination
Future Med Chem. 2016;8(3):271-85. doi: 10.4155/fmc.15.190. Epub 2016 Feb 24.

Unveiling new chemical scaffolds as Mnk inhibitors.

Author information

1
Centre for Drug Discovery & Development, Sansom Institute for Health Research, Centre for Cancer Biology, School of Pharmacy & Medical Sciences, University of South Australia, Adelaide, South Australia 5001, Australia.

Abstract

The discovery of small molecules that selectively inhibit Mnks is considered of paramount importance towards deciphering the exact role of these proteins in carcinogenesis and to further validate them as anti-cancer drug targets. However, the dearth of structural information of Mnks is a major hurdle. This study unveils the 7H-pyrrolo[2,3-d]pyrimidine derivatives as potent inhibitors of Mnks. ATP and substrate competition assays showed that this scaffold interacts with the ATP binding site, but not with the substrate site. Screened against a panel of cancer cells, Mnk inhibitors were most potent against MV4-11 acute myeloid leukemia cells. The induction of apoptosis was shown to be mediated by downregulation of Mcl-1.

KEYWORDS:

AML; CGP57380; Mnk kinase inhibitors; anti-cancer drug discovery; eIF4E phosphorylation

PMID:
26910782
DOI:
10.4155/fmc.15.190
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center